Your Search Returned 96 tagged news reports
Newswise Dr. Tanios Bekaii-Saab, medical director of gastrointestinal oncology at The Ohio State University Comprehensive Cancer Center Arthur G...James), is leading a new, two-arm, randomized phase II pancreatic cancer clinical trial that will study
Tags:
Newswise Innovative insights into a vital tumor-suppressing mechanism that is often broken in malignant cells and a type of receptor protein that frequently goes haywire to stimulate cancer growth have earned two scientists at The University of Texas
Tags:
A blood test so sensitive that it can spot a single cancer cell lurking among a billion healthy ones is moving one step closer to being available at your doctor's office. Boston scientists who invented the test and health care
Tags:
This expression, in turn, sets the stage for malignant transformation of breast cells...About 70 percent of breast cancers are estrogen receptor positive; their growth is driven by the hormone estrogen...These genes push cells into proliferation and
Tags:
Newswise A pioneering clinical trial is testing the effectiveness in leukemia of a small molecule that shuts down MDM2, a protein that can disable the well-known tumor suppressor p53. Michael Andreeff, M.D., Ph.D., professor of Medicine and chief of
Tags:
A nationwide drug shortage that includes several cancer drugs has reached Merced. But it's not time to panic, since substitute drugs are available in some cases. Dr. Merla Puray, an oncologist at the Central Valley Cancer Center in Merced, said the
Tags:
The collaboration will bring a number of new phase I clinical trials to USC Norris, and will enable the cancer center's clinical and basic scientists to provide guidance in early phase drug development and trial design. The main mission of this
Tags:
Newswise The National Cancer Institute recently announced two five-year awards totaling nearly $4 million for a partnership between the University of New Mexico Cancer Center and Sandia National Laboratories. One $1.95 million grant will fund the
Tags:
EDT Embargo expired: 11/3/2010 5:00 PM EDT Source: Phase I trial establishes dose, catalogues side effects, hints at targeted drug's potential Newswise An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent
Tags:
Newswise Building on a plan announced in September of 2007, UC San Diego Health Sciences and the Department of Radiation Oncology are pleased to announce an agreement with Proton Health Partners, LLC (PHP) to plan, develop, and operate The UC San
Tags: